Corporate Profile
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpio’s lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications.
Stock Information ARPO (Common Stock) $3.66 + 0.07 (1.95%)
ExchangeOTCQB
Volume6,000
Today's Open$3.59
Previous Close$3.59
Data as of 04/26/18 3:23 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

 
Stock chart for: ARPO.PK.  Currently trading at $3.66 with a 52 week high of $6.75 and a 52 week low of $3.45.
Upcoming Events
There are currently no events scheduled.